In-Depth Exam Of 18 Analyst Recommendations For Amgen

Within the last quarter, Amgen AMGN has observed the following analyst ratings:

Within the last quarter, 18 analysts provided 12-month price targets for Amgen. The average target is $293.06, with a high estimate of $326.00 and a low estimate of $240.00.

Get a quick summary of 18 analysts' ratings for Amgen over the last 3 months. More bullish views suggest a positive outlook, while more bearish views imply a negative sentiment.

A notable 5.07% increase in the average price target has occurred over the past month.

Explore the analyses of financial experts and analysts, gaining insights into their recent exams for Amgen. The Ratings Table below delivers a detailed overview of the actions undertaken by key analysts, their current ratings, and price targets. Uncover valuable perspectives on possible market trends and investor sentiment by understanding the perceptions of these experts towards the company.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Amgen's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Amgen analyst ratings.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Amgen displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 3.77%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.06% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Amgen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 23.97%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Amgen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.91% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: With a high debt-to-equity ratio of 7.9, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ecopetrol Reaches Analyst Target Price

In-Depth Exam Of 6 Analyst Recommendations For Intra-Cellular Therapies

Across the recent three months, 6 analysts have shared their insights on Intra-Cellular Therapies (NASDAQ:ITCI), expressing a variety of opinions spanning from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts provide deeper insights through their exams of 12-month price targets, revealing an average target of $84.5, a high estimate of $101.00, and a low estimate of $72.00. Marking an increase of 5.62%, the current average surpasses the previous average price target of $80.00.

A clear picture of Intra-Cellular Therapies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Intra-Cellular Therapies analyst ratings.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 75.05%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -19.28%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.02%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Intra-Cellular Therapies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.39%, the company may face hurdles in achieving optimal financial performance.

Debt Management: With a below-average debt-to-equity ratio of 0.03, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.